Innate Immune System and Inflammation in Alzheimer's Disease: From Pathogenesis to TreatmentSerpente M. · Bonsi R. · Scarpini E. · Galimberti D.
Neurology Unit, Department of Pathophysiology and Transplantation, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Milan, Italy Corresponding Author
Neurology Unit, Department of Pathophysiology and Transplantation
University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico
Via Francesco Sforza 35, IT-20122 Milan (Italy)
Immune activation and inflammation, likely triggered by amyloid-beta (Aβ) deposition, play a remarkable role in the pathogenesis of Alzheimer's disease (AD), which is the most frequent cause of dementia in the elderly. The principal cellular elements of the brain innate immune system likely to be involved in such processes are microglia. In an attempt to search for new disease-modifying drugs, the immune system has been addressed, with the aim of removing deposition of Aβ or tau by developing vaccines and humanized monoclonal antibodies. The aim of this review is to summarize the current evidence regarding the role played by microglia and inflammatory molecules in the pathogenesis of AD. In addition, we will discuss the main active and passive immunotherapeutic approaches.
© 2014 S. Karger AG, Basel
Alzheimer's disease (AD) is the most common form of neurodegenerative disease, which leads to a progressive loss of memory and cognitive functions. The neuropathological hallmarks of AD include neurofibrillary tangles formed by accumulation of hyperphosphorylated tau protein (NFTs), extracellular amyloid-beta (Aβ) plaques (senile plaques) and neuronal loss . Senile plaques are composed of a 4-kDa Aβ peptide derived from the cleavage of the amyloid precursor protein (APP) by two proteases, β and γ secretase . The Aβ peptide is thought to play a crucial role in the pathogenesis of AD. It adopts several neurotoxic forms including soluble and highly insoluble oligomers as well as proteolysis-resistant fibrils. The deposition of Aβ is the result of an imbalance between Aβ production and clearance; this imbalance leads to a situation of chronic inflammation in the brain. Amyloid deposition contributes to the activation of microglia, the principal innate immune cells of the central nervous system (CNS), and induces the production of a series of pro-inflammatory mediators such as cytokines and chemokines . Here, we highlight the current understanding of the role of the neuroimmune system in AD, with particular emphasis on the modulation of the immune system with immunotherapy as a potential disease-modifying treatment for AD.
Current evidence highlights that brain inflammation is a pathological hallmark of AD. The inflammatory reaction is mediated by pro-inflammatory cytokines, and it was first hypothesized that a chronic and self-sustaining inflammatory interaction between activated microglia and astrocytes, stressed neurons and Aβ plaques, occurs .
Activated cells produce not only pro-inflammatory cytokines but also chemokines, monocyte chemo-attractant proteins, macrophage inflammatory proteins, prostaglandins, leukotrienes, thromboxanes, coagulation factors, reactive oxygen species and other radicals, nitric oxide, complement factors, proteases, protease inhibitors and pentraxins [5,6]. In this context, Aβ plaques and tangles stimulate a chronic inflammatory reaction, inducing the expression of pro-inflammatory cytokines in glia cells . Inflammatory mediators released from activated microglia and astrocytes in turn enhance APP production and the amyloidogenic processing of APP to induce Aβ-42 peptide production . Therefore, many studies have provided evidence supporting the notion that inflammatory factors can contribute to neuronal dysfunction and cell death, either alone or along with other molecules. Cellular components of the brain which have many critical roles in the function of the brain and are involved in the inflammatory process in AD are microglia, astrocytes and, to a lesser extent, neurons.
Microglia are the main cells of innate immunity of the CNS, acting as primary mediators of inflammation, which orchestrate the endogenous immune response. In healthy CNS tissue, microglia possess a ramified morphology with a round soma and numerous branching processes. Recent evidence indicates that ramified microglia have critical physiologic roles, including supporting and protecting neuron axonal growth, as well as synaptic remodeling in brain and spinal cord development. The contributions of microglia to CNS maturation can be attributed to their actions in the phagocytosis of cellular debris, release of a variety of cell signaling factors, including neurotrophins and extracellular matrix components, and direct contact with neurons [8,9].
Microglia are rapidly activated by a number of pathologic events, including altered neuronal function, infections, traumatic injury, ischemia and inflammation. Activation results in a transition in microglial morphology to an ameboid state, which facilitates the migration of these cells to the site of damage . Two different microglial phenotypes have been characterized under specific pro- and anti-inflammatory conditions. The M1 phenotype is induced by classic activation of microglia (e.g. by lipopolysaccharide) and is characterized by the production of predominantly pro-inflammatory cytokines such as interleukin (IL)-1, IL-6, tumor necrosis factor (TNF)-α, interferon (IFN)-γ and free radicals such as nitric oxide and superoxide anions. It plays a central role in the defense against pathogens and tumor cells, but can also damage healthy cells, such as neurons and glial cells. The alternative M2 anti-inflammatory phenotype can be subdivided in two different groups. One phenotype is hallmarked by arginase-1 and induced by IL-4 or IL-13, which downregulates inflammation and promotes tissue remodeling/repair and angiogenesis . The second is a deactivated phenotype, is induced by IL-10 or tumor growth factor (TGF)-β, shows some increase in chemokine (C-C motif) receptor 2 and scavenger receptor expression and in phagocytic ability, but no increase in pro-inflammatory cytokine secretion .
Inflammatory changes are observed in the AD brain, particularly at the Aβ deposits, which are rich in activated microglia. Aβ contributes to enhance the inflammatory response by NFκB stimulation, a nuclear factor implicated in cytokine production , and also regulates the extracellular signal-regulated kinase and mitogen-activated protein kinase pathway that leads to the production of cytokines and chemokines . These molecules contribute to further neuronal dysfunction and eventually death, together with complement components and free radicals . It is important to note, however, that microglia are not the sole producers of cytokines following CNS insult. Astrocytes have also been implicated in the generation of pro-inflammatory mediators involved in neurodegenerative disorders .
Astrocytes carry out many functions, such as regulation of synaptogenesis and angiogenesis, which promote neuronal survival and maturation . In the AD brain, it has been shown that astrocytes are associated with Aβ deposits, suggesting that these lesions generate chemotactic molecules that mediate astrocyte recruitment and activation. During the neuroinflammatory process of AD, reactive astrocytes release and overproduce many different factors, including cytokines and chemokines [18,19] such as β-subunit of S100 protein, S100β, IL-1β, IL-6, TNF-α, IFN-γ-stimulated protein (IP)10 and TGF-β2, which could in turn induce the astrocytes reactivation . These reactivated astrocytes could secret more inflammatory molecules to upregulate the APP mRNA and protein levels in neurons, thereby leading to an enhanced Aβ generation from the APP on the neuronal membrane surface. Thus, Aβ, astrocytes, cytokines and neuronal APP could exert a vicious cycle in AD immunoneuropathology . Aβ could also be generated from astrocytes stimulated with pro-inflammatory molecules. It has been demonstrated that IFN-γ in combination with TNF-α or IL-1β could induce primary human astrocytes or astrocytoma cells to produce Aβ .
During the early stage of AD, Aβ-triggered activated astrocytes, rather than microglia activation, initiate a neuroinflammatory cascade in which the pro-inflammatory cytokines and chemokines have autocrine and paracrine effects through interactions between astrocytes, neurons and microglia . Thus, the Aβ-reactivated astrocytes might contribute substantially to cytokine-mediated inflammation in early AD pathogenesis.
Neurons seem to play a role in the inflammatory process of AD and have been implicated in the production of inflammatory products. Neurons are able to produce several cytokines, such as IL-1 , IL-6  and TNF-α . The neuron production of these pro-inflammatory products may trigger further inflammatory processes that worsen the environment and lead to neuronal toxicity and death .
Cytokines are signaling molecules, responsible for the cross-talk between cells of the immune system and neuroendocrine system. They are produced by macrophages and lymphocytes, as well as by microglia and astrocytes in the CNS. Cytokines are commonly classified in two categories: pro-inflammatory cytokines such as IL-1, TNF-α, IFN-γ, IL-12, IL-18, granulocyte-macrophage colony-stimulating factor and anti-inflammatory cytokines such as IL-4, IL-10, IL-13, IFN-α and TGF-β. This classification depends on their biological activities: if cytokines promote inflammation they are called pro-inflammatory cytokines, otherwise if they suppress the activity of pro-inflammatory cytokines they are called anti-inflammatory cytokines. The biological effects induced by cytokines include cell growth and differentiation, the stimulation or inhibition of cell proliferation, cytotoxicity/apoptosis, antiviral activity, inflammatory responses and upregulation of the expression of surface membrane proteins.
Several cytokines are produced by neurons or glia and there are a number of reports indicating changes in their levels in the AD brain, blood and cerebrospinal fluid (CSF). Levels of IL-1α, IL-1β, IL-6, TNF-α, granulocyte-macrophage colony-stimulating factor, the type B of IL-8 receptor and the receptor for CSF-1 are increased in AD brain tissue [26,27].
Recently, it has become clear that there are many interactions between cytokines and components of the AD senile plaques. In particular, cytokines can stimulate secretion of a number of the other proteins found in senile plaques  and they may interact with Aβ. IL-1, for example, regulates APP processing and Aβ production in vitro . In turn, fibrillar Aβ has been affirmed to increase neurotoxic secretory products, pro-inflammatory cytokines and reactive oxygen species . During inflammation, the pro-inflammatory cytokines are secreted by microglia and astrocytes surrounding Aβ neuritic plaques, inducing microglial activation, astrogliosis, and further secretion of pro-inflammatory molecules and amyloids, thus regulating the intensity and duration of the immune response .
As previously pointed out, the classical pro-inflammatory cytokines involved in neurodegeneration are IL-1, IL-6 and TNF-α. The IL-1 family of cytokines includes IL-1α and IL-1β, which trigger cell activation upon binding with specific membrane receptors. IL-1 is an immunoregulatory cytokine that is overexpressed within affected cerebral cortical regions of the AD brain and carries out many functions, such as enhancing neuronal acetylcholinesterase activity, microglial and astrocyte activation, and induction of S100β overexpression by reactive astrocytes . The early overexpression of IL-1 in AD has led to the suggestion that it plays a key role in plaque evolution. In particular, IL-1 promotes the synthesis  and processing of APP and may therefore promote further amyloid production and deposition in plaques.
IL-6 is a pleiotropic cytokine strongly induced under pathological conditions and its detrimental effect is associated with several CNS disorders. On the other hand, IL-6 may also have anti-inflammatory and immunosuppressive properties; in fact it regulates neuronal survival , promotes astrogliosis  and activates microglia . All the cells involved in the inflammatory process in AD seem capable of synthesizing IL-6 .
TNF-α plays a central role in initiating and regulating the cytokine cascade during inflammatory or disease states. Glial cells secrete TNF-α in response to pathological stimuli, which activate apoptosis, cytotoxicity and immune activation . By contrast, TNF-α has been reported to play a trophic or protective role in neuronal survival  in the AD brain.
Taking into account cytokine levels in CSF, which is thought to be the biological fluid that best reflects the ongoing brain pathology, IL-11 was found to be significantly increased in AD subjects as compared to controls, whereas IL-6 mean levels did not differ between patients and controls. The highest peaks were observed in patients with a less severe degree of cognitive deterioration, therefore suggesting a role of IL-11 in the early phases of neurodegeneration .
The chemokines family consists of over 50 different molecules that induce chemotaxis, tissue extravasation and modulation of leukocyte function during inflammation . Recent studies have focused on understanding the role of chemokines and their receptors in AD, since they have been found to be upregulated in resident CNS cells in the AD brain . It is likely that chemokines, produced by senile plaques, play an important role in recruiting microglia and astrocytes to the site of Aβ deposition. In vitro studies have demonstrated the ability of Aβ to stimulate the production of IL-8, IP10, monocyte chemo-attractant protein-1, macrophage inflammatory protein (MIP)-1α and MIP-1β from human monocytes and microglia cultured from rapid autopsies of AD . Furthermore, in reactive astrocytes MIP-1α has been detected nearby plaque-associated inflammation and neurodegeneration .
Chemokines are also altered in CSF from patients compared with controls. Galimberti et al.  demonstrated that IP10 concentration was elevated in CSF from patients with MCI and mild impaired AD, but not in patients with AD with a severe cognitive decline and positively correlated with the Mini Mental State Examination score. Conversely, monocyte chemo-attractant protein-1 and IL-8 levels were significantly increased in all individuals with cognitive impairment as compared with age-matched healthy controls.
To date, anticholinesterase inhibitors and memantine are used to manage cognitive and behavioral symptoms of AD, but the effects of these treatments are limited and they do not avoid the progression of the disease . The demonstration of an inflammatory role in the pathogenesis of AD, and the observation that nonsteroidal anti-inflammatory drugs protect against the development of AD , has led to the development of clinical trials with anti-inflammatory drugs as a treatment option for patients with AD. Nevertheless, despite these premises, in prospective studies all drugs tested failed to slow the progression of cognitive decline in patients with mild-to-moderate AD. Thus, nonsteroidal anti-inflammatory drugs are no longer considered to be viable treatment options for AD patients, as well as other approaches targeting oxidative damage, metals, etc. [see  for review].
The recent additional advances in the identification of biomolecular mechanisms and biomarkers for AD has led to the concept that novel treatments should modify disease pathogenic mechanisms in early phases (before the occurrence of full dementia). Since the deposition of Aβ is the key event in AD pathogenesis, many new therapeutic approaches aim to inhibit Aβ production or aggregation and to clear Aβ from the brain . Among the various strategies to influence Aβ deposition, immunotherapy is the most studied disease-modifying approach.
Active immunization implies the administration of synthetic intact Aβ peptide or fragments of Aβ conjugated to a carrier protein, leading to the production of specific antibodies. An alternative approach of immunotherapy involves passive administration of monoclonal anti-Aβ antibodies which produce an immune response without requiring a pro-inflammatory T cell reaction .
The first evidence indicating that the use of antibodies could be a potential therapeutic approach was reported in 1996 by Solomon et al. , who observed in vitro that antibodies directed against the N-terminal amino acids of Aβ peptide inhibited the formation of amyloid fibrils. Then, in 1999, Schenk et al.  demonstrated that active immunization with Aβ in young PDAPP transgenic mice overexpressing the APP gene prevented the formation of senile plaques, neuritic dystrophy and astrogliosis, and removed the preformed lesions in older mice. Further studies confirmed these results and showed that removal of plaques was also associated with an improvement in learning and memory tasks . In parallel with the active immunization, Bard et al.  demonstrated for the first time the possible important role of passive immunization; this study established that the peripheral injection of anti-Aβ monoclonal antibodies reduced the Aβ load by up to 86% in the brains of AD transgenic mice. Plaque clearance was shown to occur through fragment crystallizable (Fc) receptor-mediated phagocytosis by microglial cells, with no evidence of T cell response activation .
Other studies have demonstrated that Fc receptor interactions are not necessarily required for Aβ removal , suggesting that other mechanisms may also be involved in the Aβ clearance with active and passive immunotherapy. One of these proposed mechanisms of action is called peripheral sink, and thanks to this mechanism the formation of antigen-antibody complexes in the periphery allows the sequestration of amyloid away from the brain and prevents the deposition of new plaques. The third hypothesis proposes that the formation of antigen-antibody complexes alters the conformation of Aβ molecules, decreasing the chance of senile plaques forming . Following these promising results immunotherapy was rapidly translated into the clinic.
Given the promising preclinical results described above, AN1792, a synthetic Aβ peptide, was the first vaccine tested in clinical trials . A phase I controlled study was started in a cohort of 80 subjects with mild-to-moderate AD. Of all the subjects who received AN1792, 53% developed a positive anti-AN1792 antibody response at one or more points during the trials. In 2001, a multicenter, randomized, placebo-controlled, phase II double-blind clinical trial was started in a cohort of 300 AD patients. Although the adverse events reported during the initial study were either mild or moderate in nature, 6% of all patients who received active therapy developed aseptic meningoencephalitis. The trial was halted after 2-3 injections. At the time of suspension of dosing due to meningoencephalitis, over 90% of patients had received 2 of the planned 6 injections of AN1792/placebo. The study has been modified to allow safety follow-up for at least 9 months after the last injection. Despite the limited number of administrations, 20% of the patients treated with AN1792 were classified as antibody responders . The final results of the trial were published in 2005 .
In 2006 Nicoll et al.  presented the neuropathological findings of patients who had received 2-5 doses of AN1792. A marked reduction in senile plaque deposition was noted in the temporal cortex of patients that had developed anti-Aβ antibodies. Subsequently, additional studies confirmed these data; in particular, Holmes et al.  published long-term findings of AN1792-treated subjects up to 5 years after the last injection of the vaccine. Despite the observation of plaque removal, immunization had no effect on long-term survival or clinical outcomes.
Based on the hypothesis that the use of full-length amyloid peptide in AN1792 could have resulted in T cell autoimmune response that caused the meningeal inflammation, subsequent efforts have focused on second-generation amyloid vaccine design. The aim was to promote the humoral and not a cellular immune response . The first second-generation vaccine tested in AD patients was CAD106, which is composed of the Aβ amyloid 1-6 peptide coupled with Qβ carrier. The Aβ1-6 peptide derives from the N-terminal B cell epitope of Aβ that avoids T cell activation. Administration of CAD106 to APP transgenic mice showed a reduction of Aβ accumulation in the brain. A 52-week study with CAD106 included 58 patients with mild-to-moderate AD in 2 cohorts. Injection-site erythema was the most frequent side effect observed, but nasopharyngitis was also reported. No clinical or subclinical cases of meningoencephalitis were observed. CAD106 was associated with an Aβ antibody response in 16 out of 24 patients in cohort 1 and 18 out of 22 patients in cohort 2. The data reported from this trial suggest that CAD106 has a favorable safety profile and acceptable antibody response in AD patients. To date other vaccines are under clinical investigation, such as ACI-24, Affitope AD-02, Affitope AD-03, ACC-001, UB-311 and V-950 [see  for review].
Passive immunotherapeutic approaches are being investigated in parallel with active therapies due to serious side effects of active immunization. The direct administration of monoclonal antibodies against Aβ has been trailed in humans. This approach is an alternative solution to avoid an undesirable T cell-induced inflammation and it is theoretically safer and offers more control over the active immunotherapy. Despite significant side effects such as cerebral amyloid angiopathy observed with this approach , at least 11 passive immunotherapy trials are currently ongoing.
Two humanized monoclonal antibodies have been initially developed: bapineuzumab (clone 3D6), directed against the N-terminal region of Aβ peptide , and solanezumab (clone m266), directed against Aβ central region . Antibodies against the N-terminal region can recognize all Aβ structural forms (monomers, oligomers and fibrils) as well as the APP, suggesting that this epitope is always exposed during Aβ fibrillogenesis . Bapineuzumab is the prototypal anti-Aβ N-terminus antibody that displays anti-aggregating properties in vitro and in vivo . Prior to the completion of the phase II study, a phase III trial with bapineuzumab was initiated. The results of these trials did not show overall efficacy but a small subset of patients, i.e. the ApoE noncarriers who received the second lowest of the four doses six times, had responded well by 78 weeks. Subsequent trials in noncarriers were negative and 2 trials in ApoE4 carriers were initiated but then discontinued due to a lack of effect .
Antibodies against the central region of Aβ only bind monomers and do not enter the CNS. It was observed that these antibodies act via a peripheral sink mechanism. The best characterized antibody direct to the Aβ central region is solanezumab, which provides an increase of plasma Aβ in treated patients. Two large phase II trials have been conducted with solanezumab. In the first, a significant reduction in cognitive decline (42%) in mild AD was observed, but results were not replicated in the second trial . There are also antibodies directed against the Aβ C-terminal region, but their mechanism of action is not yet fully understood. Wilcock et al.  have designed a deglycosylated version of an anti-C-terminal antibody (2H6 clone) to avoid the side effects observed, including cerebral amyloid angiopathy. The humanized version of 2H6, ponezumab, is now in phase II clinical trials [see  for a review]. Several studies in vivo have shown that the use of modified antibodies significantly increases the removal of plaques in the brain and the reduction in the severity of side effects . Consequently, engineered antibodies have emerged as a promising alternative to treat AD . There are several types of modified antibodies, versatile molecules that can be genetically engineered to produce various formats, such as fragment antigen binding, single-chain antibodies (scFvs), V-domain and bispecific antibodies. The smaller fragments retain the specificity and often affinity of the parental antibody but display different pharmacokinetic and biochemical characteristics compared to the larger IgG format. Moreover, their low molecular weight is predicted to facilitate their passage across the blood-brain barrier . Therefore, current efforts are now focusing on improving the safety and tolerability of passive immunotherapy by using recombinant antibody fragments or Fc-engineered antibodies, which lack effector functions and are less prone to triggering deleterious side effects.
Natural anti-amyloid antibodies have been found in human intravenous immunoglobulins (IVIg) obtained from the pooled plasma of healthy blood donors. In 2010, Magga et al.  showed that in the mouse brain the IVIg, administrated at the peripheral level, penetrated the blood-brain barrier and bound to Aβ fibrils. Two phase I studies have been carried out in the last few years (www.alzforum.org), showing cognitive stabilization or even a slight ADAS-cog improvement.
However, in 2013, Dodel et al.  published the largest completed trial assessing IVIg in AD patients. The authors, in accordance with previous studies, suggested that IVIg have acceptable safety profiles, but have no effects on cognition.
The most advanced alternative hypothesis of AD, in addition to amyloid causality, is tau hyperphosphorylation. Tau phosphorylation leads to its dissociation from microtubules within the cells and to the formation of neurotoxic neurotrophic factors. Aβ immunotherapy results in a very limited indirect clearance of tau aggregates in dystrophic neuritis, showing the importance of developing parallel and specific immunotherapeutic approaches directed against pathological tau protein . Vaccination approaches have been considered, but the development of a successful therapy is complicated by the fact that tau protein is intracellular. The first attempt to use full-length human recombinant tau in its unphosphorylated form for immunization of wild-type mice caused tau pathology, astrogliosis and encephalomyelitis. This effect was probably due to the size of the immunogen . Subsequently, in tangle mouse models, both active and passive immunization with tau peptides phosphorylated at serine 396 and 404 (FITC-tau379-408) or tau antibody, reduced tau pathology and prevented cognitive impairment [69,70].
More than 100 years after its first description, AD remains the most frequent and studied neurodegenerative disease. The results obtained in the last few years have better clarified some genetic and molecular aspects of the basis of AD, including the role of genes, the inflammatory factors mainly involved in the pathology and brain immune cells that play a critical role in AD pathogenesis, microglia and astrocytes. In early stages of AD, microglia is activated in response to the formation of amyloid plaques and vice versa. In the areas of heavy Aβ concentration in the CNS of AD patients, microglia are able to phagocytose and degrade Aβ, exerting their neuroprotective properties, but, at the same time, they are also capable of producing many pro-inflammatory factors including cytokines and chemokines. During the progression of disease, an increase in Aβ production occurs, as well as an inadequate Aβ clearance and continued production of neurotoxic inflammatory products that contribute to neurodegeneration. For all these reasons the therapeutic approaches that inhibit Aβ production and aggregation or, alternatively, clear Aβ from the brain, are the most attractive. In this framework, the immunotherapy, active and passive, is the most studied and promising approach. The initial attempts to translate the successful preclinical results into safe and effective AD therapies have led to the development of serious and severe side effects in some patients. Furthermore, large phase III trials with vaccines or passive immunization failed to demonstrate any effect on cognition, therefore suggesting that targeting only the Aβ cascade may not represent the ‘cure' for AD, as there are other mechanisms implicated in the pathophysiology of the disease. For instance, Aβ lesions are not associated with clinical symptoms and the total amyloid load remains stable through clinical stages of the disease, even if there is a progressive cognitive and functional impairment, whereas tau pathology seems to be much more related to the clinical presentation and to the progression of the disease .
For the future, the new generation of immunotherapies will have to show a major ability to clear Aβ and an acceptable safety profile. In addition, biomarkers should be used to select patients to be included in clinical trials in order to exclude the recruitment of patients with non-AD dementia. Moreover, the removal of plaques could be not sufficient to halt the disease progression because the neuronal loss is too consistent in the time of the start of therapy. Therefore, clinical trials should be carried out as early as possible during the course of the disease with the hope that targeting Aβ earlier in the disease process will provide better clinical outcomes.
Neurology Unit, Department of Pathophysiology and Transplantation
University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico
Via Francesco Sforza 35, IT-20122 Milan (Italy)
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.